{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:39:34Z","timestamp":1792676374444,"version":"4.5.0"},"reference-count":56,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immune-deficient mice, reconstituted with human stem cells, have been used to analyze human immune responses in vivo. Although they have been used to study immune responses to xenografts, allografts, and pathogens, there have not been models of autoimmune disease in which the mechanisms of the pathologic process can be analyzed. We have found that reconstituted \u201chumanized\u201d mice treated with anti\u2013CTLA-4 Ab (ipilimumab) develop autoimmune disease characterized by hepatitis, adrenalitis, sialitis, anti-nuclear Abs, and weight loss. Induction of autoimmunity involved activation of T cells and cytokine production, and increased infiltration of APCs. When anti\u2013CTLA-4 mAb\u2013treated mice were cotreated with anti-CD3 mAb (teplizumab), hepatitis and anti-nuclear Abs were no longer seen and weight loss did not occur. The anti-CD3 blocked proliferation and activation of T cells, release of IFN-\u03b3 and TNF, macrophage infiltration, and release of IP-10 that was induced with anti\u2013CTLA-4 mAb. We also found increased levels of T regulatory cells (CD25+CD127\u2212) in the spleen and mesenteric lymph nodes in the mice treated with both Abs and greater constitutive phosphorylation of STAT5 in T regulatory cells in spleen cells compared with mice treated with anti\u2013CTLA-4 mAb alone. We describe a model of human autoimmune disease in vivo. Humanized mice may be useful for understanding the mechanisms of biologics that are used in patients. Hepatitis, lymphadenopathy, and other inflammatory sequelae are adverse effects of ipilimumab treatment in humans, and this study may provide insights into this pathogenesis and the effects of immunologics on autoimmunity.<\/jats:p>","DOI":"10.4049\/jimmunol.1302455","type":"journal-article","created":{"date-parts":[[2014,6,19]],"date-time":"2014-06-19T02:04:30Z","timestamp":1403143470000},"page":"587-596","source":"Crossref","is-referenced-by-count":59,"title":["Humanized Mice as a Model for Aberrant Responses in Human T Cell Immunotherapy"],"prefix":"10.1093","volume":"193","author":[{"given":"Nalini K","family":"Vudattu","sequence":"first","affiliation":[{"name":"Department of Immunobiology, Yale University School of Medicine , New Haven, CT 06520"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Waldron-Lynch","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale University School of Medicine , New Haven, CT 06520"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy A","family":"Truman","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale University School of Medicine , New Haven, CT 06520"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songyan","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale University School of Medicine , New Haven, CT 06520"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Preston-Hurlburt","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale University School of Medicine , New Haven, CT 06520"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Torres","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Yale University School of Medicine , New Haven, CT 06520"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurice T","family":"Raycroft","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale University School of Medicine , New Haven, CT 06520"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J","family":"Mamula","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale University School of Medicine , New Haven, CT 06520"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevan C","family":"Herold","sequence":"additional","affiliation":[{"name":"Department of Immunobiology, Yale University School of Medicine , New Haven, CT 06520"},{"name":"Department of Internal Medicine, Yale University School of Medicine , New Haven, CT 06520"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,7,15]]},"reference":[{"key":"2025030707222664600_r1","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1073\/pnas.1222878110","article-title":"Genomic responses in mouse models poorly mimic human inflammatory diseases","volume":"110","author":"Seok","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030707222664600_r2","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.4049\/jimmunol.172.5.2731","article-title":"Of mice and not men: differences between mouse and human immunology","volume":"172","author":"Mestas","year":"2004","journal-title":"J. Immunol."},{"key":"2025030707222664600_r3","doi-asserted-by":"crossref","first-page":"e49213","DOI":"10.1371\/journal.pone.0049213","article-title":"Islet-specific CTL cloned from a type 1 diabetes patient cause beta-cell destruction after engraftment into HLA-A2 transgenic NOD\/scid\/IL2RG null mice","volume":"7","author":"Unger","year":"2012","journal-title":"PLoS ONE"},{"key":"2025030707222664600_r4","doi-asserted-by":"crossref","first-page":"68ra10","DOI":"10.1126\/scitranslmed.3001830","article-title":"Human CD3 transgenic mice: preclinical testing of antibodies promoting immune tolerance","volume":"3","author":"Kuhn","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"2025030707222664600_r5","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1182\/blood-2010-12-326926","article-title":"Efficient differentiation and function of human macrophages in humanized CSF-1 mice","volume":"118","author":"Rathinam","year":"2011","journal-title":"Blood"},{"key":"2025030707222664600_r6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.clim.2004.04.006","article-title":"Rejection of human islets and human HLA-A2.1 transgenic mouse islets by alloreactive human lymphocytes in immunodeficient NOD-scid and NOD-Rag1(null)Prf1(null) mice","volume":"112","author":"Banuelos","year":"2004","journal-title":"Clin. Immunol."},{"key":"2025030707222664600_r7","doi-asserted-by":"crossref","first-page":"15589","DOI":"10.1073\/pnas.1005566107","article-title":"Humanized nonobese diabetic-scid IL2rgammanull mice are susceptible to lethal Salmonella Typhi infection","volume":"107","author":"Libby","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030707222664600_r8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nri2017","article-title":"Humanized mice in translational biomedical research","volume":"7","author":"Shultz","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"2025030707222664600_r9","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1196\/annals.1394.002","article-title":"Humanized NOD\/LtSz-scid IL2 receptor common gamma chain knockout mice in diabetes research","volume":"1103","author":"Shultz","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2025030707222664600_r10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","article-title":"CTLA-4 is a second receptor for the B cell activation antigen B7","volume":"174","author":"Linsley","year":"1991","journal-title":"J. Exp. Med."},{"key":"2025030707222664600_r11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"2025030707222664600_r12","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily\u2014CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"2025030707222664600_r13","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1084\/jem.183.6.2541","article-title":"CTLA-4 ligation blocks CD28-dependent T cell activation","volume":"183","author":"Walunas","year":"1996","journal-title":"J. Exp. Med."},{"key":"2025030707222664600_r14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1084\/jem.185.3.393","article-title":"CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics","volume":"185","author":"van der Merwe","year":"1997","journal-title":"J. Exp. Med."},{"key":"2025030707222664600_r15","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.290.5492.816","article-title":"Structure of murine CTLA-4 and its role in modulating T cell responsiveness","volume":"290","author":"Ostrov","year":"2000","journal-title":"Science"},{"key":"2025030707222664600_r16","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1126\/science.272.5265.1170","article-title":"Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4","volume":"272","author":"Mareng\u00e8re","year":"1996","journal-title":"Science"},{"key":"2025030707222664600_r17","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1074-7613(00)00031-5","article-title":"The CD28 and CTLA-4 receptors associate with the serine\/threonine phosphatase PP2A","volume":"13","author":"Chuang","year":"2000","journal-title":"Immunity"},{"key":"2025030707222664600_r18","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1126\/science.282.5397.2263","article-title":"Molecular basis of T cell inactivation by CTLA-4","volume":"282","author":"Lee","year":"1998","journal-title":"Science"},{"key":"2025030707222664600_r19","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"key":"2025030707222664600_r20","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S1074-7613(00)80406-9","article-title":"Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells","volume":"7","author":"Chambers","year":"1997","journal-title":"Immunity"},{"key":"2025030707222664600_r21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"2025030707222664600_r22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1084\/jem.192.2.303","article-title":"Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4","volume":"192","author":"Takahashi","year":"2000","journal-title":"J. Exp. Med."},{"key":"2025030707222664600_r23","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.4049\/jimmunol.162.10.5813","article-title":"CTLA-4-mediated inhibition of early events of T cell proliferation","volume":"162","author":"Brunner","year":"1999","journal-title":"J. Immunol."},{"key":"2025030707222664600_r24","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1073\/pnas.0910341107","article-title":"Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity","volume":"107","author":"Jain","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030707222664600_r25","doi-asserted-by":"crossref","first-page":"E2116","DOI":"10.1073\/pnas.1307185110","article-title":"Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression","volume":"110","author":"Yamaguchi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030707222664600_r26","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"100","author":"Phan","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030707222664600_r27","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1172\/JCI27745","article-title":"CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells","volume":"116","author":"Quezada","year":"2006","journal-title":"J. Clin. Invest."},{"key":"2025030707222664600_r28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.seminoncol.2010.09.003","article-title":"Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management","volume":"37","author":"Kaehler","year":"2010","journal-title":"Semin. Oncol."},{"key":"2025030707222664600_r29","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.4049\/jimmunol.174.8.5100","article-title":"Naive CD4+ T cells from lupus-prone Fas-intact MRL mice display TCR-mediated hyperproliferation due to intrinsic threshold defects in activation","volume":"174","author":"Zielinski","year":"2005","journal-title":"J. Immunol."},{"key":"2025030707222664600_r30","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.2337\/db13-0345","article-title":"Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders","volume":"62","author":"Herold","year":"2013","journal-title":"Diabetes"},{"key":"2025030707222664600_r31","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","article-title":"A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes","volume":"54","author":"Herold","year":"2005","journal-title":"Diabetes"},{"key":"2025030707222664600_r32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00125-012-2753-4","article-title":"Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial","volume":"56","author":"Herold","year":"2013","journal-title":"Diabetologia"},{"key":"2025030707222664600_r33","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus","volume":"346","author":"Herold","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"2025030707222664600_r34","first-page":"487","article-title":"Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial","volume-title":"Lancet.","author":"Sherry","year":"2011"},{"key":"2025030707222664600_r35","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II study of ipilimumab for patients with metastatic melanoma","volume":"26","author":"Weber","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"2025030707222664600_r36","doi-asserted-by":"crossref","first-page":"118ra112","DOI":"10.1126\/scitranslmed.3003401","article-title":"Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients","volume":"4","author":"Waldron-Lynch","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"2025030707222664600_r37","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/ijc.22854","article-title":"Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer","volume":"121","author":"Vudattu","year":"2007","journal-title":"Int. J. Cancer"},{"key":"2025030707222664600_r38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/OTT.S57335","article-title":"Ipilimumab in the treatment of metastatic melanoma: management of adverse events","volume":"7","author":"Della Vittoria Scarpati","year":"2014","journal-title":"Onco. Targets Ther."},{"key":"2025030707222664600_r39","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2025030707222664600_r40","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2025030707222664600_r41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"2025030707222664600_r42","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimm. Rev."},{"key":"2025030707222664600_r43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-1-60761-058-8_7","article-title":"Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease","volume":"602","author":"Pino","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"2025030707222664600_r44","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1172\/JCI23049","article-title":"T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells","volume":"115","author":"Zhu","year":"2005","journal-title":"J. Clin. Invest."},{"key":"2025030707222664600_r45","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/ncprheum0620","article-title":"B-cell lymphoproliferation in chronic inflammatory rheumatic diseases","volume":"3","author":"Hansen","year":"2007","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"2025030707222664600_r46","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.4049\/jimmunol.162.10.5784","article-title":"Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses","volume":"162","author":"Khattri","year":"1999","journal-title":"J. Immunol."},{"key":"2025030707222664600_r47","doi-asserted-by":"crossref","first-page":"168ra9","DOI":"10.1126\/scitranslmed.3004943","article-title":"Human CD8+ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice","volume":"5","author":"Zheng","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"2025030707222664600_r48","doi-asserted-by":"crossref","first-page":"E221","DOI":"10.1073\/pnas.1208573110","article-title":"CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire","volume":"110","author":"Verhagen","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2025030707222664600_r49","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1182\/blood-2006-10-050724","article-title":"Physiologic and aberrant regulation of memory T-cell trafficking by the costimulatory molecule CD28","volume":"109","author":"Mirenda","year":"2007","journal-title":"Blood"},{"key":"2025030707222664600_r50","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nm.3085","article-title":"Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-\u03b1 in rheumatoid arthritis","volume":"19","author":"Nie","year":"2013","journal-title":"Nat. Med."},{"key":"2025030707222664600_r51","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/art.37910","article-title":"Dysregulation of CD4+CD25(high) T cells in the synovial fluid of patients with antibiotic-refractory Lyme arthritis","volume":"65","author":"Vudattu","year":"2013","journal-title":"Arthritis Rheum."},{"key":"2025030707222664600_r52","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1002\/eji.201041258","article-title":"NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody","volume":"41","author":"Ablamunits","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"2025030707222664600_r53","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1038\/nm924","article-title":"TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes","volume":"9","author":"Belghith","year":"2003","journal-title":"Nat. Med."},{"key":"2025030707222664600_r54","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1172\/JCI23961","article-title":"TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs","volume":"115","author":"Bisikirska","year":"2005","journal-title":"J. Clin. Invest."},{"key":"2025030707222664600_r55","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nbt.2858","article-title":"Development and function of human innate immune cells in a humanized mouse model","volume":"32","author":"Rongvaux","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"2025030707222664600_r56","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1084\/jem.181.3.1145","article-title":"Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse","volume":"181","author":"Lenschow","year":"1995","journal-title":"J. Exp. Med."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/193\/2\/587\/61450946\/1302455.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/193\/2\/587\/61450946\/1302455.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T07:47:31Z","timestamp":1741333651000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/193\/2\/587\/7955089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,7,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1302455","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,7]]},"published":{"date-parts":[[2014,7]]}}}